A B S T R A C T This report describes the effects of pharmacologic doses (3 g/d) of nicotinic acid on the plasma distribution and chemical composition of the high density lipoprotein (HDL) subfractions HDL2 and HDL3 and examines the influence of the drug on the metabolism ofthe major HDL apoproteins, apolipoproteins A-I (ApoA-I) and A-II (Apo-II).
A B S T R A C T This report describes the effects of pharmacologic doses (3 g/d) of nicotinic acid on the plasma distribution and chemical composition of the high density lipoprotein (HDL) subfractions HDL2 and HDL3 and examines the influence of the drug on the metabolism ofthe major HDL apoproteins, apolipoproteins A-I (ApoA-I) and A-II (Apo-II).
The drug lowered plasma cholesterol (15%, P < 0.05) and triglyceride (27%, P < 0.01); the former effect a result of a fall in the amount of cholesterol associated with very low density lipoproteins (31%, P < 0.02) and low density lipoproteins (36%, P < 0.02). Conversely, it raised plasma HDL cholesterol (23%, P < 0.05) and increased (by 345%) the plasma HDL2:HDL3 ratio. The latter derived from an absolute increment (646%) in circulating HDL2, coupled with a fall (47%) in HDL3. This change was not associated with major alterations in the overall cholesterol (free and esterified), triglyceride, phospholipid, or protein content of the subfractions; however, it was accompanied by substantial changes in their protein composition. In particular, the molar ratio of ApoA-I:ApoA-II in HDL3 declined from 2.7:1 to 2.1:1 during nicotinic acid treatment.
Significant perturbations of ApoA-I and ApoA-II metabolism accompanied the drug-induced HDL subfraction redistribution. Specifically, the plasma concentration of ApoA-I rose by 7% (P < 0.05) because of a decrease in its fractional catabolic rate. Moreover, whereas before treatment 6 and 94% of the plasma ApoA-I circulated with HDL2 and HDL3, after commencement of nicotinic acid therapy this distribution A portion of this work has appeared in abstract form (1) .
Received for publication 17 August 1978 and in revised form 27 December 1978. 858 became 49 and 51% in HDL2 and HDL3, respectively. ApoA-II was found mainly in HDL3, both before and during nicotinic acid treatment. Administration of the drug caused a 14% reduction in its plasma concentration (P < 0.05), which derived principally from a fall (22%, P < 0.01) in its synthetic rate.
These data suggest that the effects of nicotinic acid on the HDL subfraction distribution may be mediated via (a) net transfer of ApoA-I from HDL3 to HDL2 and (b) a reduction in ApoA-II synthesis. Our present understanding of the association between HDL and atherosclerosis indicates that such changes may have prophylactic value in the prevention of coronary artery disease. INTRODUCTION Prospective (2, 3) and retrospective (4, 5) epidemiological studies have shown that susceptibility to coronary artery disease is negatively correlated with the plasma high density lipoproteins (HDL)1 (density [D] = 1.063-1.210 gIml) cholesterol concentration, which suggests that these lipoproteins possess antiatherogenic properties. By extrapolation, these findings may explain the observed lower incidence of coronary atherosclerosis in premenopausal women than in agematched males (6) as plasma levels of HDL cholesterol are significantly higher in the former group (7) . A number of laboratories have examined this sex-related difference with HDL subfractionation techniques. For example, in an early study of this kind, Barclay et al. (8) have demonstrated that the plasma HDL subfraction 2 (HDL2) (D = 1.063-1.125 g/ml) level in premenopausal women is more than twice that found in men of the same age: an observation confirmed in recent investigations. Cheung and Albers (9) have noted a similar increase in the HDL2 cholesterol level in females, but failed to detect any intersex difference in HDL subfraction 3 (HDL3) (D = 1.125-1.210 g/ml) cholesterol, which suggests that the putative protection conferred by HDL against atherosclerosis (2) (3) (4) 10) may reside specifically in the HDL2 subfraction.
Two pharmacologic agents, nicotiniic acid and clofibrate, are known to perturb the plasma HDL subfraction distribution, thus causing a significant rise in HDL2 ( 11, 12) . Nicotinic acid is more effective in this respect, increasing the HDL2:HDL3 ratio by at least 300% (11) . This change is associated with a fall in the fractional clearance rate of total HDL protein from the plasma compartment and an increase in the ratio of apolipoprotein A-I (ApoA-I):apolipoprotein A-II (ApoA-II), the major HDL apoproteins, in the plasma (11) . Because the latter ratio is higher in HDL2 than in HDL3 (9, 13) we surmised that the altered HDL subfraction distribution produced by the drug might be associated with relative changes in the metabolism of these proteins. In this study, we have examined this possibility by measuring the kinetic parameters ofApoA-I and ApoA-II and the composition of circulating HDL2 and HDL3 before and during the administration ofnicotinic acid to five healthy subjects.
METHODS
This project was approved by the Human Research Committees of Glasgow Royal Infirmary, Baylor College of Medicine, and The Methodist Hospital. Five healthy young adults (three male, two female) were examined on two occasions, first while receiving no medication (including the contraceptive pill), and secondly during nicotinic acid administration (1 g thrice daily by mouth). The subjects had formed part ofa previously examined group (14) whose clinical, biochemical, and hematological parameters were within the normal range. They ate a regular diet and were examined as outpatients, an arrangement which minimized perturbation of their life-styles and which has been shown (15) to provide steady-state conditions suitable for turnover studies. For 3 d before and throughout the investigations, they received 300 mg of potassium iodide thrice daily to prevent thyroidal sequestration of radioiodide.
Turnover study protocol. In the first, control phase of this study, base-line measurements were made ofHDL apoprotein metabolism and of the relative distribution and composition of the HDL subfractions in each subject. Thereafter, all participants received 1.0 g of nicotinic acid thrice daily for 3 wk before reassessment of the above parameters during drug treatment.
The analytical procedures which were used have been described in detail elsewhere (14, 16, 17) . Essentially, autologous HDL was labeled with 131I-ApoA-I and 125I-ApoA-II by an in vitro transfer procedure (16, 17) , and the plasma clearance rate of the proteins was determined as described before (14) with the mathematical procedures of Matthews (18) and Berson and Yalow (19) for data analysis. Uptake of the labeled apoproteins into HDL isolated before or during nicotinic acid treatment was not measurably different, and agarose gel chromatography (14) showed that throughout both study periods the labeled tracer apoproteins remained associated with the plasma HDL fraction. The plasma concentrations of ApoA-I and ApoA-II in each subject were measured at daily intervals throughout the turnover study by previously published electroimmunoassay methods (14, 20) whose within-and between-batch coefficients of variation were 3.6 and 4.8% for ApoA-I and 4.5 and 4.6% for ApoA-II. The frequency of plasma sampling for the estimation of plasma lipids and lipoproteins is detailed elsewhere (14) . Rate (14, 20) . Finally, the relative distribution of HDL2 and HDL3 in the plasma was determined from the areas subtended by the respective peaks of each subfraction on the zonal elution profile (20) .
RESULTS
Effect of nicotinic acid treatment on plasma lipids and lipoproteins. Administration of nicotinic acid in a dose of 3 g/d lowered the plasma cholesterol and triglyceride concentrations (Table I) in this group of normal subjects by a mean of 15 (P < 0.05) and 27% (P < 0.01), respectively. The fall in cholesterol resulted from a significant reduction in the amount of that lipid transported in the very low density lipoprotein (VLDL) (D = 0.95-1.006 g/ml) (31%1, P < 0.02) and low density lipoprotein (D = 1.006-1.063 gIml) (36%1, P < 0.02) fractions of the plasma. By contrast the drug induced a substantial rise (23%, P < 0.05) in HDL cholesterol (Table I) , accompanied by alterations in the HDL subfraction distribution. Fig. 1 shows typical HDL rate zonal ultracentrifugation profiles of a male and female subject before and during treatment. In the control situation, the characteristic sex-related difference (21) in the HDL2:HDL3 ratio is evident, the male ratio being substantially lower than that of the female. Nicotinic acid produced, in the male subject, a large increase in HDL2, whereas in the female the increase in HDL2 was also accompanied by an evident reduction in the level of HDL3. Individual values for the HDL2:HDL3 ratio are given in Table II and show that this treatment consistently gave rise to a higher HDL2: HDL3 ratio in the plasma, the mean increment being 345%. Concomitant with the above changes, small but significant modifications were observed in the plasma levels of ApoA-I and ApoA-II (Table II) . Specifically, the concentration of ApoA-I rose by a mean of 7% (P < 0.05) whereas that of ApoA-II fell 14% (P < 0.05). Consequently, the plasma ratio of these proteins was significantly changed as a result of the treatment (Table II) . When compared with the control value, the ApoA-I:ApoA-II ratio increased by 26% (P < 0.01) during nicotinic acid administration.
Influence (13, 24) suggests that the C apolipoproteins (ApoC) make an important contribution, particularly as components of HDL2. Knowledge of the plasma concentrations of ApoA-I and ApoA-II (Table II) (Tables III and IV) These changes in total plasma HDL concentration were permitted calculation of the effects of nicotinic acid associated with a substantial redistribution of the HDL treatment on the distribution of the subfractions in the subfractions in the plasma, in accord with the findings plasma. The resulting data, derived from the mean of the zonal ultracentrifugation study. The males and values in Tables II-IV, are presented in Table V and females showed a respective mean increase in plasma show that, in the control situation, an average of 11% HDL2 of 784 and 395% with a fall in HDL3 of 41 and (9% in the male group, 16% in the females) of the 53%. Consequently, there was an absolute increase plasma HDL mass was HDL2, and 89% was HDL3.
(1,000% in the males; 587% in the females) in the Separate analyses of the male and female values plasma concentration of HDL2-associated ApoA-I, showed that the response to nicotinic acid therapy was accompanied by reductions in ApoA-I (37% in the essentially the same in both groups, differing only in males; 46% in the females) and ApoA-II (23% in the degree. For example, although there was a mean males; 29% in the females) in the HDL3 fraction. increase of 20% in the total plasma HDL concentration Any changes in the ApoA-II content of HDL2 were too during treatment, this resulted largely from a 30% rise small to be reliably measured. in the level of this lipoprotein in the male group. Thus, the nicotinic acid-induced increase in plasma The comparative increment in the females was only 4%. HDL2 and fall in HDL3 is accompanied by (a) a rise in Effects of nicotinic acid therapy ofapolipoprotein A metabolism. In an earlier study (17) we have shown that the turnover of '25I-ApoA-II intercalated into HDL in vitro is indistinguishable from that of endogenous ApoA-II labeled in situ in the HDL particle. Consequently, because endogenous ApoA-I and ApoA-II are catabolized identically in HDL (11, 17) , the kinetic (Tables III and IV) and from plasma ApoA-I and ApoA-II concentrations (Table II) .
t ApoA-II was barely detectable in HDL2 ofmales and females, both before and during nicotinic acid treatment.
parameters obtained for the 1251-ApoA-II/HDL tracer used in this study reflect the metabolism of ApoA-I and ApoA-II in holo-HDL and can be used, in conjunction with the measured ApoA-I and ApoA-II plasma pool sizes, to calculate the synthetic rates of these proteins. Radioiodinated ApoA-I, however, incorporated into HDL by the same in vitro transfer procedure (16, 17) , is cleared from the plasma more rapidly than its counterpart labeled in holo-HDL and is thought to reflect the catabolism of an exchangeable ApoA-I subpopulation in HDL (16) . The steady-state conditions which pertained throughout the study, as indicated by the low standard deviation in the measurements made of the subjects' body weight, urine:plasma radioactivity ratios, and plasma levels of cholesterol, ApoA-I, and ApoA-II (Tables I, II (17) . The complexities of the technique prompted our search for an alternative, simpler procedure. WVe have found that labeled ApoA-I and ApoA-II can be incorporated independently into HDL in vitro to form a product which maintains its integrity upon injection into the bloodstream (14, 17) . WVhereas the intercalated ApoA-II decays at the same rate as ApoA-I and ApoA-II labeled in holo-HDL, the plasma clearance rate of in vitro incorporated ApoA-I is consistently faster (14, 17) , which suggests that the latter represents a more rapidly metabolised HDL ApoA-I subpopulation (16) . This proposal gains support from two recently published abstracts. In the first of these, Zech et al. (25) injected radioiodinated ApoA-I and ApoA-II and found that their plasma decay curves and urine radioactivities were consistent with a model containing two plasma components, one decaying faster than the other. A similar finding was reported by Fidge et al. (26) for ApoA-I using 1251-HDL as tracer. In this study we set out to define the effects of nicotinic acid on HDL metabolism, employing 31I-ApoA-I/HDL and 125I-ApoA-II/ HDL as tracers for the rapidly metabolised ApoA-I subpopulation and holo-HDL apolipoprotein A, respectivelv. Nicotinic acid in pharmacologic doses (3-6 g/d) reduces plasma triglyceride and, to a lesser extent, cholesterol (27, 28) by lowering the level of circulating VLDL (29, 30) and low density lipoproteins (30) . In contrast, HDL cholesterol is increased (31) , an observation confirmed by this study (Table I ). The drug also affects the plasma levels of the major HDL apoproteins, ApoA-I and ApoA-II (Table II) . ApoA-I rose by 7% (P < 0.05) whereas ApoA-II fell 14% (P < 0.05), resulting in a significant (26%, P < 0.01) increase in the plasma ApoA-I/ApoA-II ratio. A similar, although much smaller, nicotinic acid-induced increment in this ratio was reported by Blum et al. (11) in HDL of D 1.09-1.21 g/ml. Because it has been shown by ourselves (Tables  III-V) and others (9) that HDL2 contains a significant fraction of the total plasma ApoA-I, extension of the density range studied by Blum et al. to encompass this HDL subfraction in its entirety would substantially augment their assessment of the plasma ApoA-I:ApoA-II ratio, particularly during nicotinic acid treatment (which raises the plasma HDL2 concentration, Table  V) . Similarly, this methodologic adjustment by increasing the measured plasma apolipoprotein A pool, particularly during nicotinic acid administration, would diminish the reported reduction in apolipoprotein A synthesis which these workers attributed to the drug. Consequently, both studies agree on the influence of nicotinic acid on HDL apolipoprotein A metabolism. This report extends our understanding of the pharmacologic effects of this treatment by detailing the changes produced by the drug on the kinetic parameters of the two major HDL proteins, ApoA-I and ApoA-II, and on the composition of the HDL subfractions. The fractional rate of removal of these proteins from the plasma measured by the 125I-ApoA-II/HDL tracer (mean FCR = 0.234 pools/d, Table VI) the ApoA-II specific activity decay data of Blum et al. (11) . This observation, coupled with the 7% rise in the plasma ApoA-I pool size, indicated that total ApoA-I synthesis had been unaffected by the drug (Table VI) . Conversely, the 14% fall in the plasma ApoA-II pool size despite an 8% decrease in its fractional rate of catabolism was good evidence that nicotinic acid significantly reduces the synthetic rate of that protein (by 22%, P < 0.01, Table VI ). Therefore, nicotinic acid diminishes the overall rate of HDL apolipoprotein A synthesis, in accord with the conclusions of Blum et al. (11) . Its influence on ApoA-I metabolism is complicated by the apparent existence of two subpopulations of this protein in the plasma (16, 25, 26 ). While we are not able to determine precisely its effects on each of these, it is clear that they respond differently. The FCR of the more rapidly metabolized pool (as measured by 131fI ApoA-I) did not change (Table VII) , whereas that of total ApoA-I (Table VI) fell significantly. The above drug-mediated changes in apoprotein metabolism accompanied major increases in the plasma HDL2:HDL3 ratio without gross perturbation of the lipid composition (Tables III and IV) or flotational properties (Fig. 1) of the subfractions. Their altered distribution readily accounts for the previously observed (11) increment in the cholesterol:protein ratio of HDL during nicotinic acid treatment, because this ratio is substantially higher in HDL2 than in HDL3 (Tables III and IV) .
The metabolic factors which trigger the increase in plasma HDL2:HDL3 during nicotinic acid therapy are difficult to evaluate because the lipoprotein appears to be affected by several direct and indirect regulatory mechanisms, some or all of which may respond to the drug. HDL is thought to be secreted by the human liver (32) in the form ofnascent particles which are then extensively modified by their participation in exchange and net transfer ofprotein components with chylomicra (24, 33) and VLDL (34, 35) . ApoA-I and ApoA-II, secreted in association with chylomicra by the gut, are quantitatively transferred to HDL during chylomicron catabolism (33) . Moreover, HDL (in particular, HDL2) serves as a plasma reservoir for ApoC. Newly synthesised chylomicra and VLDL, on their appearance in the plasma, acquire a substantial component of their ApoC complement from this reservoir and return it during their catabolism (24, 32) . This shuttle function of HDL2 in relation to ApoC metabolism has led to the suggestion (36) that transfer of surplus surface components from triglyceride-rich lipoproteins during lipolysis may be cardinal to regulation of the HDL subfraction distribution in the plasma. In this regard, it is arguable that the reduction in VLDL synthesis induced by the drug (29) might limit ApoC transfer from the HDL2 reservoir and account for the observed 247% expansion of the nonapolipoprotein A protein pool in the HDL2 density range (Tables III and  IV ) and the 646% increase in circulating HDL2 (Table V) .
The changes effected by nicotinic acid on the metabolism and disposition of ApoA-I and ApoA-II in HDL favor the proposal that the shift in mean HDL particle size may be mediated by these proteins (11) . During treatment, the rate of synthesis of ApoA-II was reduced selectively (Table VII) , producing a fall in the level ofthat protein circulating with HDL3. The ApoA-I content of the particle fell even more, evidenced by the 32% decrease in the HDL3 ApoA-I:ApoA-II molar ratio (which fell from a control value of 2.7:1 to 2.1:1 during treatment, Table IV ). Yet, the synthetic rate of ApoA-I was not altered by the drug. Consequently, there had been a net loss of ApoA-I from HDL3 with an equivalent gain in HDL2 (Table V) . These data are consistent with the suggestion that the particle size distribution over the HDL density range may be regulated by a combination of altered synchronization of ApoA-I and ApoA-II synthesis and net transfer of ApoA-I between HDL2 and HDL3. The higher ApoA-I:ApoA-II ratio in HDL2 vs. HDL3 (Tables III and IV ) and the observation that the major HDL proteins (ApoA-I, ApoA-II, and ApoC) exchange rapidly between the HDL subfractions both in vivo and in vitro (36) support this proposal.
Regulation of the plasma HDL subfraction distribution may be effected by changes in the metabolism of the HDL proteins. Such a concept links the metabolism of HDL with that ofthe other lipoproteins, in particular chylomicra and VLDL. However, it must be stated that the modulation attributed to the apoproteins may only play a minor regulatory role or even be subordinate to other as yet unrecognized processes. Consequently, the above hypotheses are presented as a framework for further study.
